Skip to content Skip to footer
Subscribe Now
PharmaShots Interview SOTIO Richard Sachse Shares Insight on SOT101 for the Treatment of Advanced Metastatic Solid Tumors
VIEWPOINTS

PharmaShots Interview: SOTIO’ Richard Sachse Shares Insight on SOT101 for the Treatment of Advanced/Metastatic Solid Tumors

In an interview with PharmaShots, Richard Sachse, Chief Medical Officer & Managing Director at SOTIO shared his views on the data of SOT101 in the P-I/Ib (AURELIO-03) study for the treatment of advanced/metastatic solid tumors Shots: The P-I/Ib (AURELIO-03) study evaluates SOT101 as monothx. & in combination with pembrolizumab in patients with advanced/metastatic solid tumors The results showed that 13 patients…
April 6, 2022

Read more

PharmaShots Interview Ikena Oncology’ Mark Manfredi Shares Insight on IK-930 for the Treatment of Solid Tumors
VIEWPOINTS

PharmaShots Interview: Ikena Oncology’ Mark Manfredi Shares Insight on IK-930 for the Treatment of Solid Tumors

In an interview with PharmaShots, Mark Manfredi, President, and CEO at Ikena Oncology shared his views on the US FDA’s IND clearance of IK-930 for the treatment of solid tumors that harbors genetic alterations in the hippo pathway Shots: The US FDA has accepted its IND application to initiate the P-I study of IK-930 for solid tumors harboring genetic alterations in the…
April 5, 2022

Read more

Viewpoints_Dr. Ian Walters
VIEWPOINTS

PharmaShots Interview: Portage Biotech’s Dr. Ian Walters Shares Insight on the Data of INT230-6 Presented at ASCO 2021

In an interview with PharmaShots, Dr. Ian Walters, CEO of Portage Biotech shared his views on the interim data from the P-II IT-01 trial evaluates the safety and efficacy of INT230-6 as both a monotherapy and in combination with pembrolizumab or ipilimumab in solid tumors Shots: The P-II IT-01 trial evaluates the safety & efficacy of INT230-6 as monothx. & in…
September 13, 2021

Read more

Viewpoints_Dennis Williams
VIEWPOINTS

PharmaShots Interview: Adaptimmune’s Dennis Williams Shares Insight About the Company’s Pathway to Bringing the First-Ever TCR T-Cell Therapy for Solid Tumors to Market

In an interview with PharmaShots, Dennis Williams, SVP Late-stage Development at Adaptimmune shared his views on the Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform and their pathway to bringing the first-ever TCR T-cell therapy for solid tumors to market along with an overview about their industry-leading T-cell therapy pipeline in solid tumors.…
August 16, 2021

Read more